Dataset Information


Paclitaxel-Coated Balloons: Review of a Promising Interventional Approach to Preventing Restenosis in Femoropopliteal Arteries.

ABSTRACT: Peripheral arterial disease (PAD), a major cause of morbidity and mortality worldwide, is characterized by intermittent claudication and is associated with chronic diseases such as diabetes and hypertension. The goal of treatment is to address the underlying cause and to modify risk factors. Although medical management is the first-line treatment of PAD, some individuals may have severe symptoms and require revascularization with percutaneous transluminal angioplasty with or without stent placement or surgery. Interventional approaches may, however, be associated with high prevalence of restenosis and subsequent complications such as critical limb ischemia and amputation. Drug-eluting balloons (DEBs) are a new interventional technology with the primary goal of preventing restenosis. We review the clinical trials and studies that assessed the efficacy and safety profile of DEB and will focus on the restenosis rate in femoropopliteal arteries including target lesion revascularization (TLR) and late lumen lesion (LLL) using different modalities of intervention such as stents and DEB. Average data collected from the trials reported included restenosis rate of 25%, 0.3?mm LLL, and 14% reduction in TLR with DEB versus uncoated balloons. Below the knee (BTK) only intervention studies were excluded from this review as endovascular approach is usually reserved for critical limb ischemia for BTK disease. Interventional approach to treat PAD with DEB appears to be a promising technology. Additional larger studies are needed to further define safety, efficacy, and longer term outcome with this novel technology.


PROVIDER: S-EPMC4870051 | BioStudies | 2016-01-01T00:00:00Z


REPOSITORIES: biostudies

Similar Datasets

1000-01-01 | S-EPMC5834842 | BioStudies
2013-01-01 | S-EPMC3648374 | BioStudies
2017-01-01 | S-EPMC5405921 | BioStudies
2020-01-01 | S-EPMC7457510 | BioStudies
2020-01-01 | S-EPMC7225207 | BioStudies
1000-01-01 | S-EPMC5939540 | BioStudies
2020-01-01 | S-EPMC7539040 | BioStudies
2016-01-01 | S-EPMC5084407 | BioStudies
1000-01-01 | S-EPMC4868867 | BioStudies
2020-01-01 | S-EPMC7336236 | BioStudies